| Molecular portraits of human breast tumours CM Perou, T Sørlie, MB Eisen, M Van De Rijn, SS Jeffrey, CA Rees, ... nature 406 (6797), 747, 2000 | 20523 | 2000 |
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications T Sørlie, CM Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, ... Proceedings of the National Academy of Sciences 98 (19), 10869-10874, 2001 | 14391 | 2001 |
| Repeated observation of breast tumor subtypes in independent gene expression data sets T Sørlie, R Tibshirani, J Parker, T Hastie, JS Marron, A Nobel, S Deng, ... Proceedings of the national academy of sciences 100 (14), 8418-8423, 2003 | 7191 | 2003 |
| Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors JR Pollack, JR (Pollack, T Sorlie, T (Sorlie, CM Perou, CM (Perou, ... PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF …, 2002 | 1484* | 2002 |
| Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial RC Coombes, LS Kilburn, CF Snowdon, R Paridaens, RE Coleman, ... The Lancet 369 (9561), 559-570, 2007 | 1105 | 2007 |
| Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients T Aas, AL Børresen, S Geisler, B Smith-Sørensen, H Johnsen, ... Nature medicine 2 (7), 811-814, 1996 | 960 | 1996 |
| Subclonal diversification of primary breast cancer revealed by multiregion sequencing LR Yates, M Gerstung, S Knappskog, C Desmedt, G Gundem, P Van Loo, ... Nature medicine 21 (7), 751-759, 2015 | 863 | 2015 |
| Long-term cultures of bone marrow–derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation GV Røsland, A Svendsen, A Torsvik, E Sobala, E McCormack, ... Cancer research 69 (13), 5331-5339, 2009 | 833 | 2009 |
| Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Geisler, B Haynes, G Anker, M Dowsett, PE Lønning Journal of Clinical Oncology 20 (3), 751-757, 2002 | 717 | 2002 |
| Genomic evolution of breast cancer metastasis and relapse LR Yates, S Knappskog, D Wedge, JHR Farmery, S Gonzalez, ... Cancer cell 32 (2), 169-184. e7, 2017 | 690 | 2017 |
| Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer A Bergamaschi, YH Kim, P Wang, T Sørlie, T Hernandez‐Boussard, ... Genes, Chromosomes and Cancer 45 (11), 1033-1040, 2006 | 617 | 2006 |
| Influence of TP53 Gene Alterations and c-erbB-2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer S Geisler, PE Lønning, T Aas, H Johnsen, Ø Fluge, DF Haugen, ... Cancer research 61 (6), 2505-2512, 2001 | 454 | 2001 |
| Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial PE Lønning, E Bajetta, R Murray, M Tubiana-Hulin, PD Eisenberg, ... Journal of Clinical Oncology 18 (11), 2234-2244, 2000 | 418 | 2000 |
| In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. J Geisler, N King, G Anker, G Ornati, E Di Salle, PE Lønning, M Dowsett Clinical cancer research: an official journal of the American Association …, 1998 | 411 | 1998 |
| Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer J Geisler, N King, M Dowsett, L Ottestad, S Lundgren, P Walton, ... British journal of cancer 74 (8), 1286-1291, 1996 | 408 | 1996 |
| Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a … A Di Leo, S Johnston, KS Lee, E Ciruelos, PE Lønning, W Janni, ... The Lancet Oncology 19 (1), 87-100, 2018 | 398 | 2018 |
| Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track–letter A Torsvik, GV Røsland, A Svendsen, A Molven, H Immervoll, ... Cancer research 70 (15), 6393-6396, 2010 | 364 | 2010 |
| Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer PE Lønning, J Geisler, LE Krag, B Erikstein, Y Bremnes, AI Hagen, ... Journal of Clinical Oncology 23 (22), 5126-5137, 2005 | 345 | 2005 |
| Mutation of GATA3 in human breast tumors J Usary, V Llaca, G Karaca, S Presswala, M Karaca, X He, A Langerød, ... Oncogene 23 (46), 7669-7678, 2004 | 321 | 2004 |
| Gene expression profiling–based identification of molecular subtypes in stage IV melanomas with different clinical outcome G Jönsson, C Busch, S Knappskog, J Geisler, H Miletic, M Ringnér, ... Clinical cancer research 16 (13), 3356-3367, 2010 | 301 | 2010 |
Stian KnappskogProfessor, University of BergenVerified email at med.uib.no